After enduring some 200 snakebites and hundreds more venom injections, one man’s blood may be the key to a universal antivenom. Over about two decades, Tim Friede has allowed venomous snakes to bite him hundreds of times,

Jacob Glanville, the CEO of a biotech company called Centivax, had a mission: to develop a universal antivenom against snakebites. There are more than 600 species of venomous snakes in the world, but they each produce different types of venom.

A new snakebite treatment combines an existing drug with antibodies from a hyperimmune reptile collector, raising both hopes and ethical concerns